MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping patients live longer.

San Diego-based MEI (NASDAQ: MEIP), licensed the compound, pracinostat, from a Singaporean biotech company in 2013. In August 2016 MEI signed an alliance with Helsinn to advance the experimental drug for patients newly diagnosed with AML who are unable to receive intensive chemotherapy due to advanced age—75 years or older—or other health reasons.

Under the deal… Read more »